{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000028","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-05-15T20:03:04+00:00","discovered_at":"2026-05-15T20:07:00.428292+00:00","generated_at":"2026-05-15T20:08:59.216053+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved","bullets":["Elected all three Class III director nominees: Arthur T. Sands (63.6M for, 16.3M withheld), Roger Dansey (79.6M for, 0.3M withheld), Paul M. Silva (59.3M for, 20.6M withheld).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026 with 83.6M for, 0.2M against, 0.02M abstentions.","Approved non-binding advisory vote on named executive officer compensation: 72.5M for, 6.9M against, 0.6M abstentions, 3.8M broker non-votes.","Approximately 81% of voting power (83.7M shares) present, establishing a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000028","json":"https://secwatch.observer/filing/0001549595-26-000028.json","markdown":"https://secwatch.observer/filing/0001549595-26-000028.md","text":"https://secwatch.observer/filing/0001549595-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/0001549595-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/nrix-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:08:59.216053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3281447d80eedc0d18d489ba1cbcfeccbbc9d41b","claim":"Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2026-05-15 meeting.","evidence_excerpt":"Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 63,592,948 16,334,570 3,819,495 Roger Dansey, M.D. 79,607,489 320,029 3,819,495 Paul M. Silva 59,298,612 20,628,906 3,819,495","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/0001549595-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"aa94185c7e9e4f65ea4801da069513ad1f127c36","claim":"Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2026 at the 2026-05-15 meeting.","evidence_excerpt":"Votes For Votes Against Abstentions Broker Non-Votes 83,555,977 166,391 24,645 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/0001549595-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"},{"claim_id":"c8156b1916608a4e71eb8635085c095f6a4ffa17","claim":"Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2026-05-15 meeting.","evidence_excerpt":"Votes For Votes Against Abstentions Broker Non-Votes 72,458,920 6,895,394 573,204 3,819,495","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/0001549595-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}